Category Archives: R&D

Patient Privacy Fears Taint UK Innovation Plans

By Julian Upton | Published: December 5, 2011
Patient Privacy Fears Taint UK Innovation Plans The Conservative arm of the UK’s coalition government flexed its private-sector-friendly muscles again on Monday with the announcement that the National Health Service should be ‘opened up’ to private healthcare firms. In a pharma-friendly speech peppered with the usual buzzwords, Prime Minister David Cameron said: “The end-game is for [...]
Also posted in healthcare | Tagged , , , , | Leave a comment

Tiered Pricing Not Always a Win-Win

By Ben Comer | Published: November 22, 2011
Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.
Also posted in Corporate Responsibility, Emerging Markets, Global, IP, Manufacturing, Market Access, Strategy, pricing | 2 Comments

It's Industry's Problem: A Fresh Take on R&D Costs

By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
Also posted in Global, IP, leadership | Tagged , , , , | 2 Comments

European Pharma 1981-2011: Survival of the Fittest?

By Guest Blogger | Published: October 5, 2011
This month sees Pharmaceutical Executive magazine reach its 30th birthday. In line with that milestone, Reflector assesses what the last three decades have meant for European pharma — and shows how the game has changed beyond recognition. Thirty years is a long time in any industry. The coalmining industry, the market for air travel, or telecommunications [...]
Also posted in Emerging Markets, Europe, Global, Guest Blog, IP, Pharm Exec Magazine, Regulatory, healthcare, leadership | Tagged , , , , , , | Leave a comment

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

By Ben Comer | Published: September 28, 2011
R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Also posted in FDA, Market Access, Strategy, leadership, pricing | Tagged , , , , | Leave a comment